The FDA recently removed non-ambulatory Duchenne patients from the gene therapy's indication, which Sarepta hopes to have reinstated.

Doctors can use the test, developed by Endeavor Health in collaboration with GenomicMD, to direct more aggressive treatment ...

With $1.6 million from CPRIT, investigators are testing an endogenous T-cell therapy that has certain advantages over CAR ...

The British company's CAR T-cell therapy will now be available through the National Health Service in England and Wales.

Itvisma has the same active ingredient as Novartis' Zolgensma, but is approved for a broader population of older patients with an intrathecal formulation.

The NSGC is still pushing to achieve Medicare recognition for its members, and said that a counterpart bill will be introduced in the Senate in coming months.

The EC considered data from the TRANSCEND NHL 001 trial, in which 83 percent responded to the CAR T-cell therapy and 72 percent had a complete response.

From 2017 until Oct. 1, 2025, sponsors have submitted around 50 INDs seeking to begin clinical testing of individualized ...

NEW YORK – Tempus AI has scooped up the pharmacogenetics assets held by OneOme, a company that recently went out of business due to financial difficulties.

The firm plans to submit results from the Phase III OptiTROP-Lung05 trial to regulators in China, seeking approval for sac-TMT and Keytruda in PD-L1-positive patients.

The CAP committee recommended that pathologists use mass spectrometry to determine the subtype for amyloidosis patients being considered for treatment.

The firm plans to explore biomarkers of response for PIN-5018 and its other pipeline candidates to identify best responders to treatment.